The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
about
P1343
Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft modelBreakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer typesThe conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRαTranscription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data.FIP1L1/PDGFR alpha-associated systemic mastocytosis.Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CELTyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect.Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAEosinophils: changing perspectives in health and disease.Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignanciesTargeting mutated tyrosine kinases in the therapy of myeloid leukaemias.The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.Chronic myeloproliferative disorders: a tyrosine kinase tale.Eosinophilia: secondary, clonal and idiopathic.Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivoQuizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoformsCurrent concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.
P2860
Q28480622-E4DE5213-9CB4-46DF-BA62-1EC276C9E4E9Q28486949-436D5D35-88DE-4316-9098-D489237DF214Q28535951-C2E66206-3F50-4D7D-B704-3D93D08123ADQ33538943-F2B192C1-0E45-4B53-9FCD-C645419E4908Q34051023-2D0A1490-0E60-4AD3-A061-8B1AD9A0F780Q34241738-49B99E48-3DED-43B8-8587-DB51E8BC510FQ34249210-D2575945-1114-457E-B776-5CE696D19E3FQ35114558-EC60A853-D763-4870-B363-3F2F902F2075Q35170969-85F3C9C3-225D-47AC-8AEF-D39D729A216CQ35608465-2EE08AB1-F5A5-4E81-8FC7-458E9F2FAA10Q35782893-9E6D2F17-8F87-4A88-9052-AE8D327AA664Q35848279-89FC4E44-D636-4B0D-AE3C-1CEC832977B8Q35849213-1EB3AC54-FF29-40E0-BBE4-AF806D364D24Q36182741-0E329054-F913-4217-940B-75E6418DF6C4Q36337918-4B9E76F4-130F-45D9-A791-40C45BC9B78AQ36471689-596AB2D9-B291-4550-B7F6-2E2522CCAC89Q36658028-97D586FE-FC53-4134-BDDE-D5220A345A5BQ36798620-224C273D-8E52-47DF-B3DC-D6B5FB301035Q36811905-BAED9023-5F95-4E21-9322-74FEA0F13040Q37598944-9410F103-0A06-4659-A580-C4DBC1B752ADQ37755233-9B2FFF6A-F88F-4C19-BE1C-D96BB2D8889EQ38131481-3F6FA1EB-ECD1-49EF-B637-22E3B89BDA66Q39407253-F9585443-0A4A-44F2-A7E1-0F088606672DQ39969275-102C347F-9ABB-4046-B1D6-FA968328B519Q40097189-5B6E407C-DA78-40B9-841D-5E48BFDA45DDQ40211560-D4056450-7489-4602-9AAE-93145B23DE62Q40286391-C16583F8-4046-47BF-A33B-22F996B1AB34Q40395721-238FDB06-DAEF-4530-A95D-70D0DACBF489Q42371492-5E8AFF3B-8DAC-4EB4-B082-0C7B9E0410B5Q46889637-59703E2D-7A97-48CD-B8A2-0FE50D13E66BQ53553773-8F7C8247-8F4C-4907-96C3-F6A995426921Q53641005-69E060CC-1DE1-4BA7-87EB-C0C48AA13CFF
P2860
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@ast
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@en
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@nl
type
label
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@ast
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@en
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@nl
prefLabel
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@ast
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@en
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@nl
P2093
P1433
P1476
The EOL-1 cell line as an in v ...... chronic eosinophilic leukemia
@en
P2093
Brian J P Huntly
D Gary Gilliland
Hilmar Quentmeier
James D Griffin
Peter Marynen
P304
P356
10.1182/BLOOD-2003-07-2479
P407
P4510
P577
2004-04-01T00:00:00Z